TNGX R&D to Revenue
Tango Therapeutics Inc · R&D to Revenue
TNGX R&D to Revenue
Latest reported0.00%period ending
TNGX Quarterly R&D/Revenue (229.72% → 0.00%)
Latest values, visible window
High-resolution chart · PNG
TNGX r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 0% | |
| 0% | |
| 0% | |
| 57.2652% | |
| 1,011.6944% | |
| 675.8531% | |
| 824.3138% | |
| 286.5771% | |
| 194.4855% | |
| 588.2398% | |
| 577.0392% | |
| 252.9724% | |
| 196.4036% | |
| 486.2817% | |
| 453.767% | |
| 415.3757% | |
| 411.3845% | |
| 422.5425% | |
| 378.4815% | |
| 323.0146% | |
| 105.1011% | |
| 234.8888% | |
| 164.785% | |
| -115.2384% | |
| 219.767% | |
| 229.7177% |